An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects

An Approved Vaccine To Treat Prostate Cancer Has Few Side Effects.
The newly approved restorative prostate cancer vaccine, Provenge, is conservative and has few airs effects, a new study finds. In April, the US Food and Drug Administration approved the vaccine for use in men with advanced prostate cancer who had failed hormone therapy. "Provenge was approved based on both cover and clinical data," said prima donna researcher Dr Simon J Hall, bench of urology at Mount Sinai Medical Center in New York City.

This refuge data shows that there are very limited side effects. The superiority of the vaccine for patients with metastatic hormone-resistant prostate cancer is that it has fewer side stuff than chemotherapy, which is the only other treatment option for these patients. In addition, Provenge has improved survival over chemotherapy.

The mean survival time for men given Provenge is 4,5 months, although some patients saw their lives extended by two to three years. "This is a newly nearby treatment, with very limited standpoint effects, compared to anything else that a man would be considering in this state". Hall was to present the results on Monday at the American Urological Association annual convergence in San Francisco.

Data from four phase 3 trials, which included 904 men randomized to either Provenge or placebo, showed the vaccine extended survival, improved nobility of viability and had only mild side effects. In fact, more than 83 percent of the men who received Provenge were able to do appear as activities without any restrictions, the researchers noted.

In terms of incidental effects, the most common were flu-like symptoms such as chills, fever and headache, which were seen in 3,5 percent of the men. Usually it took only a hour or two for the symptoms to resolve. More serious side effects, such as infusion reactions, insincere 3,5 percent of the patients. Cerebrovascular problems affected 3,5 percent of those who received the vaccine and 2,6 percent of those who received placebo, Hall's gang found.

Dr Nelson Neal Stone, a clinical professor of urology and diffusion oncology at Mount Sinai School of Medicine in New York City, said that "the view effects are for instance having the flu and they can be managed with aspirin". However, Stone pointed to one big drawback to Provenge: cost. "I've heard $30000, I've heard $90000. I have no goal what it's active to cost. And who's going to pay for it?" he said.

Provenge is a therapeutic (not preventive) vaccine that is made from the patient's own corpse-like blood cells. Once removed from the patient, the cells are treated with the treatment and placed back into the patient. These treated cells then cause an immune response, which in constitutional kills cancer cells, while leaving normal cells unharmed. According to the FDA, Provenge is given intravenously in a three-dose organize delivered in two-week intervals.

The vaccine was developed by Seattle-based Dendreon Corp, which conducted monogram studies among men with advanced prostate cancer who had already failed par hormone treatment. According to American Cancer Society estimates, more than 192000 fresh cases of prostate cancer are diagnosed in the United States each year, and 27360 men Euphemistic depart from the disease.

Prostate cancer is the most common form of cancer diagnosed in American men, after husk cancer. More than 2 million American men who have had prostate cancer at some point are still in the land of the living today get more information. The death rate is going down and the disease is being found earlier, according to the cancer society.